Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial.

Current medical research and opinion - 1 Jan 2012

Wang Ling, Zhou Liya, Hu Haitang, Lin Sanren, Xia Jielai

Abstract excerpt

OBJECTIVE: The new proton pump inhibitor (PPI), ilaprazole performed better at the dose of 10 mg/d relative to 5 or 20 mg/d in a previous phase II trial. A larger phase III trial was carried out to confirm the efficacy and safety of ilaprazole (10 mg/d) compared with omeprazole (20 mg/d) and provide some characteristics of the relationship between ilaprazole metabolism and CYP2C19 for later studies. RESEARCH...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Anti-Ulcer Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Benzimidazoles

Share to Cytochrome P-450 CYP2C19

Share to Double-Blind Method

Share to Duodenal Ulcer

Share to Omeprazole

Source

Identifiers

PMID: 22070512
DOI: 10.1185/03007995.2011.639353

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial.PMID 22070512Read ↗

Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.Semantic proximity Read ↗

Pathophysiology, Risk Factors, and Advances in the Management of Peptic Ulcers: A Comprehensive ReviewSemantic proximity Read ↗

Pharmacologic Therapies in Gastrointestinal Diseases.Semantic proximity Read ↗

Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes.Semantic proximity Read ↗

Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications.Semantic proximity Read ↗

Proton pump inhibitors and recurrent bleeding in peptic ulcer disease.Semantic proximity Read ↗

Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Semantic proximity Read ↗

CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.Semantic proximity Read ↗

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Semantic proximity Read ↗

Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.Semantic proximity Read ↗

Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.Semantic proximity Read ↗

Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.